Researchers use gene editing technology to cure a baby’s leukemia

A very unique and new method of treatement was given to two girls with leukemia. They both have slowly started to recover. The target was to kill their cancers using a special gene-editing method, and it actually worked.
This treatment was first given to a girl named Layla.A team of experts from the Great Ormond Street Hospital had conducted this experiment. This team could not give any conclusions back in November as to whether the girl was indeed cured from leukemia.


This indicates yet another astounding take on how effective gene editing has become to treat conditions.But how exactly this treatment is done?Also known as CAR-T cell therapy, the main function of it is that,it targets specific cancer cells by the addition of a gene to immune cells. Virus helps in adding the said gene.


The virus carries a part of the patient’s RNA with a specific pattern that will cut at specific site and it correlates to a pre-programmed code. It allows it to instantly kill without damage certain genes with cancer properties.
Even though it has the promising results, the CAR-T cell therapy is not guaranteed .

One of the drawback of this method is that it is expensive and it is not easily available because patients need to be treated using their own modified immune cells. This completely destroys  the option of using other regular cells as the body will treat them as foreign objects which are viable for an attack.
However, there are still some good news. A paris based company known as Cellectis, has developed a gene-editing tool which allows the use of immune cells from an outsider without the host body attacking them.
These new gene-editing methods will open doors for improvising mmune cancer therapies. Researchers have now started using these methods, with two cancer trials using CRISPR-edited cells which is undergoing in China and the U.S.

READ  5 facts you must know before you invest in biotech sector

Get your free subscription for Industry updates

Thank you for subscribing.

Something went wrong.